Building Digital Measures for PD? DEEP can help!
Clinical trials in PD have relied on snapshot, clinic-based assessments for too long. We're changing that: bringing pharma, biotech, researchers, patients, and tech vendors together to build validated, regulatory-ready digital endpoints for Parkinson's.
The Challenge
Parkinson's Disease affects millions of people worldwide. Yet the clinical tools used to measure it in drug trials have barely evolved. Today's gold standard test is administered in a clinic setting. It captures a 10-minute snapshot. It misses tremor during the night, motor fluctuations at home, and the real burden patients live with every day.
Over 50 digital technologies now target PD symptoms. Pharma, vendors, and researchers are working in isolation, duplicating effort and slowing validation.
Without validated, regulatory-aligned endpoints, even the most promising digital tools cannot be used in pivotal trials or accepted by health authorities.
Why work with DEEP?
If your pipeline includes a Parkinson's disease program, one of the hardest questions you'll face is: what do I measure, and how do I get regulators to trust it? The MDS-UPDRS has been the standard for decades, but it's a snapshot taken in a clinic. It misses tremor at night, motor fluctuations at home, and the day-to-day reality your drug is actually treating.
DEEP works with pharma and biotech companies to identify, build, and validate fit-for-purpose digital measures for PD - directly aligned to your drug target, your patient population, and your regulatory pathway. We work with companies individually on their own programs, and we run a broader collaborative initiative for those who want to go further.
The PD Mission
Beyond individual programs, DEEP runs an industry-wide collaborative initiative to build a shared, reusable digital measurement framework for PD - open to pharma, biotech, tech vendors, researchers, and patient organizations.
We're launching a multi-stakeholder initiative to build a digital measurement framework for Parkinson's disease, one that is evidence-driven, patient-centered, and regulatory-ready. Using DEEP's proven Digital Measure Strategy Framework (DMSF), we unify the people and the evidence needed to create validated digital endpoints at scale. "Over 20 global pharma companies are advancing PD programs as of 2025. This initiative gives all of them a shared, regulatory-aligned foundation."
Who's Involved
This initiative is designed to create value for every stakeholder involved in advancing Parkinson's research and care.
Pharma & Biotech
Align digital measurement concepts with your drug targets and use validated endpoints in your clinical programs. Reduce time and cost spent reinventing the wheel by leveraging our shared evidence infrastructure.
Technology Vendors
Access a clear blueprint of PD digital measurement standards. Understand exactly what pharma and regulators need from your tools, and build for scalability and regulatory acceptance from day one.
Academia & Research
Extend foundational Parkinson's research through structured collaboration with industry. Contribute to and benefit from a growing, curated evidence base that accelerates the path from discovery to application.
Patient Advocacy Organizations
Ensure that patient and clinician priorities are at the center of what gets measured. Bring the patient voice into endpoint design, so the trials that follow actually measure what matters to people living with PD.
Experts & Key Opinion Leaders
Shape the industry with your expertise. Help future-proof clinical trials for both regulatory acceptance and genuine patient impact, and establish yourself as a leader in the next generation of PD endpoints.
Working with DEEP on you PD program gives you:
Faster Pathways to Effective Therapies
Shared evidence and regulatory alignment compress timelines from discovery to validated endpoint, accelerating the whole field.
Strengthened Trial Digital Endpoints
Validated, regulatory-ready digital measures replace fragile legacy assessments; giving trials more sensitive, objective, and trusted primary and secondary endpoints.
Expert strategic support across the DMSF
Structured validation and multi-stakeholder consensus build the regulatory confidence needed for digital endpoints to count in pivotal trials.
Improved Monitoring & Care for PD Patients
Better endpoints mean better drugs, and better drugs mean more people living better lives with Parkinson's disease.
Accelerated Clinical Trials & Innovation
Reusable, standardized measurement infrastructure reduces redundant work across pharma, cutting time and cost from every program that follows.
A Unified Approach to Digital Measure Adoption
Industry-wide harmonization removes the fragmentation that has stalled digital measure adoption - replacing siloed efforts with a shared foundation.
The Science Behind the Mission
Using DEEP's Digital Measure Strategy Framework (DMSF), we have already conducted a maturity assessment mapping digital solutions across PD measurement domains spanning movement, speech, cognition, and sleep. With more than 50 digital technologies currently targeting PD symptoms, the landscape is rich but fragmented. Our work consolidates and structures this evidence into a reusable, regulatory-aligned foundation.
Join the Mission. Shape the Future of PD Trials.
Whether you represent a pharma company, a technology vendor, a research institution, or a patient advocacy organization, your involvement matters. This initiative succeeds when the right people are at the table. Contact us here.